Does it cause heartburn or gastric discomfort?

No. The protocol's gastric profile is neutral because the enzymatic action is selective. Boswellia 65% AKBA inhibits the 5-LOX pathway without touching COX-1, the enzyme that protects the gastric mucosa. Unlike NSAIDs (ibuprofen, diclofenac), there is no gastric-barrier erosion with prolonged use. Taking it with a meal maximizes curcumin absorption and softens any individual sensitivity.

Does it interact with anticoagulants or other medications?

Generally compatible with most classes. Three clinical notes that matter: Anticoagulants (warfarin, rivaroxaban, apixaban, clopidogrel, aspirin) can be potentiated by high-dose turmeric and Boswellia, so consult your hematologist before starting. Pre- or post-surgery: pause the protocol for the 7 days leading up to the procedure. Shellfish allergy: the glucosamine is plant-fermented GlucosaGreen, safe to take.

How soon can I notice the first change?

Milestones observed in studies: Day 7 to 14, initial modulation of the inflammatory cascade and reduced morning stiffness. Day 21 to 30, stable plasma concentration of hyaluronic acid and improved range of motion. Day 60 to 90, glucosamine incorporation by chondrocytes and sustained decline in inflammatory markers. Individual response varies.

Can I combine this with physical therapy or exercise?

Yes. The protocol complements mechanical approaches (physical therapy, strength training, load management). Biochemical modulation reduces the inflammation that hinders tissue recovery. Mechanical stimulus guides remodeling. Let your physical therapist know about the supplementation so load progression stays aligned.

MMP-13

Context

Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteases that degrade extracellular matrix proteins. More than 20 MMPs exist in humans with tissue-specific roles. In articular cartilage, MMP-13 is the dominant collagenase because it preferentially cleaves type II collagen, the fibrillar collagen that forms the structural scaffold of cartilage.

MMP-13 expression is not constitutive in healthy adult cartilage. Chondrocytes upregulate MMP-13 in response to inflammatory signals (IL-1, TNF-alpha), mechanical stress, and developmental programs. In osteoarthritic cartilage, MMP-13 levels are sharply elevated. Genetic knockout of MMP-13 in mouse models of osteoarthritis reduces cartilage degradation, confirming its causal role.

Why it matters for joint health

MMP-13 reframes the conversation about joint aging. Cartilage does not break down through mechanical wear alone; it breaks down through enzymatic action. This means interventions that modulate the upstream signaling driving MMP-13 expression (NF-kB modulators like curcumin, 5-LOX modulators like AKBA) address the mechanism more directly than interventions that only target symptoms. Supporting matrix synthesis in parallel (glucosamine, HA) addresses the opposite side of the MMP/synthesis balance.

References

Wang M, Sampson ER, Jin H, et al. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Research & Therapy. 2013. PMID 23298463
Mehana EE, Khafaga AF, El-Blehi SS. The role of matrix metalloproteinases in osteoarthritis pathogenesis. Life Sciences. 2019. PMID 31351082

Matrix Metalloproteinase-13

Context

Why it matters for joint health

Related terms

References